
ENGN Stock Forecast & Price Target
ENGN Analyst Ratings
Bulls say
enGene Holdings Inc. possesses a promising outlook due to its RMAT designation for detalimogene, which enhances its potential to capture significant market share, especially in the community practice setting. The Company is set to benefit from expansion opportunities through its LEGEND Cohorts 2, 3, and 4, which could broaden its addressable market to include earlier disease stages and active surveillance. Additionally, while research and development expenses have risen to $22.6 million in Q3 2025, this investment reflects strategic growth aimed at pivotal clinical studies and manufacturing advancements, aligning with the Company's long-term objectives in the biotechnology sector.
Bears say
The analysis indicates a negative outlook for enGene Holdings, primarily due to the significant risk associated with regulatory approval delays, which could adversely affect the company's stock performance. Additionally, the operational complexities and high adverse event rates linked to TAR-200's administration may hinder its market acceptance, creating competitive pressures that could further challenge enGene's positioning. Lastly, the potential for increased dissatisfaction regarding TAR-200's operational burden may accelerate the adoption of competing gene therapies, negatively impacting enGene's prospects.
This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ENGN Analyst Forecast & Price Prediction
Start investing in ENGN
Order type
Buy in
Order amount
Est. shares
0 shares